Validated RP-HPLC method for the simultaneous analysis of gemcitabine and LY-364947 in liposomal formulations

Current Drug Targets

Volumn 14, Issue 9, 2013, Pages 1061-1069

  Bansal, Shyam S ^a   Celia, Christian ^a,b   Ferrati, Silvia ^a   Zabre, Erika ^a   Ferrari, Mauro ^a   Palapattu, Ganesh ^a,c   Grattoni, Alessandro ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CHIETI   (Italy)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Chemotherapeutics; Gemcitabine; Liposomes; LY 364947; RP HPLC; Simultaneous analysis

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; GEMCITABINE; LIPOSOME; LY 364947; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; ARTICLE; CALIBRATION; DRUG STABILITY; ELUTION; ENCAPSULATION; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LINEARITY; LIPOPHILICITY; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; PARTICLE SIZE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ROBUSTNESS; SPECIFICITY; VALIDATION PROCESS; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATTLE; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEOXYCYTIDINE; DRUG STABILITY; LIPOSOMES; PANCREATIC NEOPLASMS; PYRAZOLES; PYRROLES;

EID: 84881328726     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/13894501113149990165     Document Type: Article

References (39)

1. Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC. Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res 2011; 4: 1158-1171.
2. Bertino P, Piccardi F, Porta C, et al. Gaudino, Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res 2008; 14: 541-548.
3. Ghosal N, Mais K, Shenjere P, et al. Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma. Brit J Oral Max Surg 2011; 49: 510-515.
4. Harrington KJ, El-Hariry IA, Holford CS, et al. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 1100-1107.
5. Safran H, Miner T, Resnick M, et al. Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer. Am J Clin Oncol 2008; 31: 140-144.
6. Kano MR, Bae Y, Iwata C, et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci USA 2007; 104: 3460-3465.
7. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol 2006; 17: 7-12.
8. Mita Y, Ajiki T, Kamigaki T, et al. Antitumor effect of gemcitabine on orthotopically inoculated human gallbladder cancer cells in nude mice. Ann Surg Oncol 2007; 14: 1374-1380.
9. Habermehl D, Kessel K, Welzel T, et al. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat Oncol 2012; 7: 28.
10. Karachaliou N, Kouroussis C, Papakotoulas P, et al. A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. Cancer Chemoth Pharm 2012; 69: 1345-1352.
11. Mori K, Kamiyama Y, Kasai H, Kodama T. A Phase II Study of First-Line Chemotherapy with Weekly Carboplatin Plus Gemcitabine in Advanced Non-Small Cell Lung Cancer. Chemotherapy 2012; 58: 78-83.
12. Sonpavde G, Sternberg CN. Neoadjuvant Chemotherapy for Invasive Bladder Cancer. CurR Urol Rep 2012; 13: 136-146.
13. Anton K, Glod J. Targeting the tumor stroma in cancer therapy. Curr Pharm Biotechnol 2009; 10: 185-191.
14. Mutlu P, Ural AU, Gunduz U. Differential gene expression analysis related to extracellular matrix components in drug-resistant RPMI- 8226 cell line. Biomed Pharmacother 2012; 66: 228-231.
15. Swartz MA, Iida N, Roberts EW, et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res 2012; 72: 2473-2480.
16. Witz IP. Tumor-microenvironment interactions: dangerous liaisons. Adv Cancer Res 2008; 100: 203-229.
17. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6: 506-520.
18. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003; 100: 8621-3.
19. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004; 3: 1011-1022.
20. Brown LF, Dvorak AM, Dvorak HF. Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease. Am Rev Respir Dis 1989; 140: 1104-1107.
21. Minowa T, Kawano K, Kuribayashi H, et al. Increase in tumour permeability following TGF-beta type I receptor-inhibitor treatment observed by dynamic contrast-enhanced MRI. Br J Cancer 2009; 101: 1884-1890.
22. Peng SB, Yan L, Xia X, et al. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry 2005; 44: 2293-2304.
23. Kleeff J, Beckhove P, Esposito I, et al. Pancreatic cancer microenvironment. Int J Cancer 2007; 121: 699-705.
24. Cabral H, Matsumoto Y, Mizuno K, et al. Accumulation of sub- 100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 2011; 6: 815-823.
25. Paolino D, Sinha P, Fresta M, Ferrari M. In: Encyclopedia of Medical Devices and Instrumentation; J.G. Webster, Ed. John Wiley & Sons, Inc.; pp 437-495.
26. Cosco D, Paolino D, Cilurzo F, Casale F, Fresta M. Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases. Int J Pharm 2012; 422: 229-237.
27. Cosco D, Paolino D, Maiuolo J, Russo D, Fresta M. Liposomes as multicompartmental carriers for multidrug delivery in anticancer chemotherapy. Drug Deliv Transl Res 2011; 1: 66-75.
28. Federico C, Morittu VM, Britti D, Trapasso E, Cosco D. Gemcitabine- loaded liposomes: rationale, potentialities and future perspectives. Int J Nanomedicine 2012; 7: 5423-5436.
29. Paolino D, Cosco D, Racanicchi L, et al. Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. J Control Release 2010; 144: 144-150.
30. Pili B, Reddy LH, Bourgaux C, Lepêtre-Mouelhi S, Desmaële D, Couvreur P. Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation. Nanoscale 2010; 2: 1521-1526.
31. Jantscheff P, Ziroli V, Esser N, et al. Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model. Clin Exp Metastasis 2009; 26: 981-992.
32. Celia C, Malara N, Terracciano R, et al. Liposomal delivery improves the growth-inhibitory and apoptotic activity of low doses of gemcitabine in multiple myeloma cancer cells. Nanomedicine 2008; 4: 155-166.
33. Marangon E, Sala F, Caffo O, Galligioni E, D'Incalci M, Zucchetti M. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry. J Mass Spectrom 2008; 43: 216-223.
34. Vainchtein LD, Rosing H, Thijssen B, Schellens JH, Beijnen JH. Validated assay for the simultaneous determination of the anticancer agent gemcitabine and its metabolite 2',2'- difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry. Rapid Commun Mass Spectrom 2007; 21: 2312-2322.
35. Lanz C, Fruh M, Thormann W, Cerny T, Lauterburg BH. Rapid determination of gemcitabine in plasma and serum using reversedphase HPLC. J Sep Sci 2007; 30: 1811-1820.
36. Vandana M, Sahoo SK.Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer. Biomaterials 2010; 31: 9340-9356.
37. Guidance for Industry Q2B Validation of Analytical Procedures: Methodology. Available at: http://www.fda.gov/downloads/Regulator% 20yInformation/Guidances/UCM128049.pdf [accessed December 08, 2011].
38. Gemcitabine Hydrochloride for Injection. Available at: http://ehs.lilly.com/msds/msds_gemcitabine_hydrochloride_for_inj ection.pdf [accessed March 08, 2012].
39. Available at: http://r2d2drug.org/Drug/DrugDetail.aspx?ID=SPDD03985&keyWords=SPDP03550 [accessed March 08, 2012].